Company intelligence / Profile preview

NXI Therapeutics

Ownership: Private
Employees: ~10
Development stage: Other

Overview

The company is developing selective immunosuppressants targeting the coronin 1 pathway. Preclinical models show that coronin 1 depletion allows long-term acceptance of genetically unrelated organ transplants, prevents Graft vs Host Disease, protects from several autoimmune disorders, while maintaining normal lifespan without infections and cancer emergence[6].

Therapeutic areas: Immunology
Modalities: Small moleculesantibodies
Industry: Biotech

Beyond the preview

Go deeper on NXI Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NXI Therapeutics.

Explore the full profile